Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TTR | P02766 | 1/20 | 0.33 |
| ▸ | ITGA4 | P13612 | 1/20 | 0.33 |
| ▸ | ITGB7 | P26010 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18472335 | 1.00 | TTR (0.33) | TTRITGA4ITGB7MEN1KMT2A | |
| SCHEMBL18472377 | 0.90 | ALDH1A1 (0.32) | ITGA4ITGB7MEN1KMT2AALDH1A1 | |
| SCHEMBL18472378 | 0.87 | — | — | |
| SCHEMBL18472328 | 0.85 | MTNR1A (0.31) | — | |
| SCHEMBL18472380 | 0.85 | — | — | |
| SCHEMBL16970661 | 0.84 | ATM (0.38) | ITGA4ITGB7MAPT | |
| SCHEMBL18472381 | 0.84 | ALDH1A1 (0.43) | ITGA4ITGB7MEN1KMT2AALDH1A1 | |
| SCHEMBL16979723 | 0.83 | — | — | |
| SCHEMBL18472331 | 0.83 | — | — | |
| SCHEMBL18472394 | 0.83 | ITGA4 (0.33) | TTRITGA4ITGB7MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10034847-B2 | Beta-substituted beta-amino acids and analogs as chemotherapeutic agents | QUADRIGA BIOSCIENCES, INC. (US) | 2018-07-31 | — | — | US | disclosed |
| US-9861599-B2 | Beta-substituted beta-amino acids and analogs as chemotherapeutic agents | QUADRIGA BIOSCIENCES, INC. (US) | 2018-01-09 | — | — | US | disclosed |
| US-20160346240-A1 | METHODS OF CHEMOTHERAPY USING CHEMOTHERAPEUTIC AGENTS BASED ON BETA-SUBSTITUTED BETA-AMINO ACIDS AND ANALOGS | QUADRIGA BIOSCIENCES, INC. | 2016-12-01 | — | — | US | disclosed |
| US-20160296484-A1 | BETA-SUBSTITUTED BETA-AMINO ACIDS AND ANALOGS AS CHEMOTHERAPEUTIC AGENTS | QUADRIGA BIOSCIENCES, INC. | 2016-10-13 | — | — | US | disclosed |
| US-20160289172-A1 | BETA-SUBSTITUTED BETA-AMINO ACIDS AND ANALOGS AS CHEMOTHERAPEUTIC AGENTS | QUADRIGA BIOSCIENCES, INC. | 2016-10-06 | — | — | US | disclosed |
| US-9394237-B2 | β-substituted β-amino acids and analogs as chemotherapeutic agents | QUADRIGA BIOSCIENCES, INC. (US) | 2016-07-19 | — | — | US | disclosed |
| US-20160185710-A1 | BETA-SUBSTITUTED BETA-AMINO ACIDS AND ANALOGS AS CHEMOTHERAPEUTIC AGENTS | QUADRIGA BIOSCIENCES, INC. | 2016-06-30 | — | — | US | disclosed |
| US-20150218086-A1 | BETA-SUBSTITUTED BETA-AMINO ACIDS AND ANALOGS AS CHEMOTHERAPEUTIC AGENTS | QUADRIGA BIOSCIENCES, INC. | 2015-08-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150218086-A1 | BETA-SUBSTITUTED BETA-AMINO ACIDS AND ANALOGS AS CHEMOTHERAPEUTIC AGENTS | SLC7A1, SLC3A2, SLC1A5 | TTR 1131/4885ITGA4 2497/4885ITGB7 1562/4885 |
| US-20160289172-A1 | BETA-SUBSTITUTED BETA-AMINO ACIDS AND ANALOGS AS CHEMOTHERAPEUTIC AGENTS | SLC7A1, SLC3A2, SLC1A5 | TTR 1131/4885ITGA4 2497/4885ITGB7 1562/4885 |
| US-20160346240-A1 | METHODS OF CHEMOTHERAPY USING CHEMOTHERAPEUTIC AGENTS BASED ON BETA-SUBSTITUTED BETA-AMINO ACIDS AND ANALOGS | BCAT1, CDC25C, BCAT2 | TTR 533/4885ITGA4 3872/4885ITGB7 2614/4885 |
| US-20160296484-A1 | BETA-SUBSTITUTED BETA-AMINO ACIDS AND ANALOGS AS CHEMOTHERAPEUTIC AGENTS | SLC7A1, SLC3A2, SLC1A5 | TTR 1131/4885ITGA4 2497/4885ITGB7 1562/4885 |
| US-10034847-B2 | Beta-substituted beta-amino acids and analogs as chemotherapeutic agents | SLC7A1, SLC3A2, SLC1A5 | TTR 1131/4885ITGA4 2497/4885ITGB7 1562/4885 |
| US-20160185710-A1 | BETA-SUBSTITUTED BETA-AMINO ACIDS AND ANALOGS AS CHEMOTHERAPEUTIC AGENTS | SLC7A1, SLC3A2, SLC1A5 | TTR 1131/4885ITGA4 2497/4885ITGB7 1562/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.